Reports and Filings

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™ and MetaMx™

AB569 Principal Scientist

Lead scientist for AB569 which targets Respiratory Pseudomonas Infections

BORG Peptide Solid Surface Interface Scientists

Lead scientists for BORG Peptides

Treatments for Inflammation Scientists

Lead scientists for Treatments for Inflammation

Recent News

March 4th 2021

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

February 26th 2021

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners

Contact us

+1 647 428 7031
info@archbiopartners.com
Mailing Address
27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
Canada M4T 2M5

Copyright Arch BioPartners 2020. All Rights Reserved. Legal notices.

PAGE TOP | TYPE SIZE | | RESET

Reports and Filings